NZ336371A - Human gene therapy using DNA/RNA cassette expression systems - Google Patents

Human gene therapy using DNA/RNA cassette expression systems

Info

Publication number
NZ336371A
NZ336371A NZ336371A NZ33637196A NZ336371A NZ 336371 A NZ336371 A NZ 336371A NZ 336371 A NZ336371 A NZ 336371A NZ 33637196 A NZ33637196 A NZ 33637196A NZ 336371 A NZ336371 A NZ 336371A
Authority
NZ
New Zealand
Prior art keywords
dna
dna sequence
gene therapy
expression systems
human gene
Prior art date
Application number
NZ336371A
Inventor
Marc Gagne
Original Assignee
9071 7125 Quebec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9509461.1A external-priority patent/GB9509461D0/en
Application filed by 9071 7125 Quebec Inc filed Critical 9071 7125 Quebec Inc
Publication of NZ336371A publication Critical patent/NZ336371A/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Use of a recombinant DNA expression system comprising a 5' expression regulation DNA sequence and a decretory DNA and a secretory DNA sequence encoding a secretory signal sequence operatively linked to a DNA sequence encoding for therapeutic protein, peptide o antisense nucleotide selected from the group consisting of bacteriocins, lanthionins, lactoferrin and lysosyme, wherein said expression regulation DNA sequence and said secretory DNA sequence are capable of directing the in vivo expression of said DNA sequence of a therapeutically effective amount of said protein, peptide or antisense nucleotide as a active ingredient in a composition to prevent or treat an infectious disease in a human.
NZ336371A 1995-05-10 1996-05-10 Human gene therapy using DNA/RNA cassette expression systems NZ336371A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9509461.1A GB9509461D0 (en) 1995-05-10 1995-05-10 DNA molecules and constructs and their use in the treatment of mastitis
NZ307139A NZ307139A (en) 1995-05-10 1996-05-10 Method of genetically treating and preventing mastitis and other diseases in animals.

Publications (1)

Publication Number Publication Date
NZ336371A true NZ336371A (en) 2001-01-26

Family

ID=26307011

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ336371A NZ336371A (en) 1995-05-10 1996-05-10 Human gene therapy using DNA/RNA cassette expression systems

Country Status (1)

Country Link
NZ (1) NZ336371A (en)

Similar Documents

Publication Publication Date Title
AU6787894A (en) Adenoviral vectors of animal origin and use in gene therapy
CA2189250A1 (en) Cytokine regulatory agents and methods of use in pathologies and conditions associated with altered cytokine levels
GR3030382T3 (en) Cytokine restraining agents.
DE69434447D1 (en) PLASMIDE FOR GENE THERAPY
GB2268492B (en) Protein based delivery system
GB2292382B (en) Obesity (OB) peptides capable of modulating body weight of animals, allelic variants, analogs and fragments thereof, derivatives, nucleic acid sequences, vect
MY132189A (en) Recombinant obese (ob) proteins
MX9708854A (en) Gene therapy for effector cell regulation.
WO2002044320A3 (en) Human elongase genes and uses thereof
NZ334041A (en) Anti-chlamydial activity of BPI (bactericidal/permeability increasing proteins) protein products against chlamydia infected host cells
WO1997022695A3 (en) Nucleotide sequences, proteins, drugs and diagnostic agents for treating cancer
HK1002284A1 (en) Novel implant and novel vector for the treatment of acquired diseases
NZ336371A (en) Human gene therapy using DNA/RNA cassette expression systems
BG103905A (en) New bpc peptide salts with organoprotective activity, method for their preparation and application in medicine
WO1999046381A3 (en) Human fgf gene and gene expression products
MX9604539A (en) Modified amino acids for drug delivery.
ES2140307A1 (en) Nucleic acids regulating gene expression.

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: IMMUNOPHARMA INC, CA

Free format text: OLD OWNER(S): 9071-7125 QUEBEC INC.

RENW Renewal (renewal fees accepted)